NR3C2 and Primary hyperaldosteronism: More research is needed in this area as it raises several important questions, not least the impact of this glucocorticoid excess in patients who are not surgically cured of their primary hyperaldosteronism but receive mineralocorticoid receptor antagonist therapy which has no antiglucocorticoid effect.